| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2017. Refer to TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | ibrutinib (Imbruvica®) | |
| Formulation | 140 mg hard capsule | |
| Reference number | 2027 | |
| Indication | Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 10/06/2016 | |
| Date of issue | 15/06/2016 | |
| NICE guidance | ||